高级制剂研究员

南京济群医药科技股份有限公司是一家高成长性的，专门从事新药研发、技术转让、技术服务和医药新产品产业化的创新型生物医药企业。 

Nanjing Gritpharma Co., Ltd. is an innovative biomedical enterprise that has high growth, specializing in new drug research an d development, technology transfer, technical service an d new product industrialization.  

公司由医药行业从业多年的专业人士发起，有 国家特殊人才支持计划人才 、国家 创新创业人才计划支持的专利家 领衔创新团队，怀揣梦想，富于激情，熟悉药物研发和申报的各个流程以及政策法规、指导原则的要求，熟练掌握药物合成、分析、制剂、药代、药效、安评以及化合物分离鉴定相关的技术和仪器设备。依托上海药物所、中国药科大学等高校资源，建立了强大的顾问专家团。 

Nanjing Gritpharma Co., Ltd. was established by professionals who was experienced in pharmaceutical industry. The scientific research innovation team, which included  National special talent support program  members,  innovative an d entrepreneurial talents  members, helps our company attract researchers with years of experience in drug research an d development. Most of the researchers have doctor s Ｏr master s degree, Ｏr scientific research personnel of middle an d senior titles. The R&D team is not only young an d energetic, but also familiar with the processes, policies, regulations an d guidelines through the drug research an d reporting, an d proficient in technologies an d equipment about drug synthesis, analysis, formulation, pharmacokinetics, safety evaluation, an d identification. At the same time, our company has a strong group of advisory experts from universities such as Shanghai Institute of medicine, China Pharmaceutical University, Nanjing University an d Nanjing Tech University. With the leading of the group of advisory experts, our R&D team becomes more mature an d experienced.

公司本着 创新、人本、精业、济群 的理念，不断发展和完善自身的业务能力，建立高效的新药项目管理系统和完整的新药项目研发体系，力图引进创新型的产品，满足日益增长的中国临床需求，愿意和国际同行一起合作，立志成为中国创新时代的生物医药领军企业！

Our company keeps developing an d improving its own capacity in line with  joint innovation, human-oriented, proficiency an d mass-beneficial  business philosophy, establishing efficient management system of new drug project an d the complete development system of new drug project research, trying to introduce innovative products, meeting the growing demand for Chinese clinical, willing to cooperate with international Ｃounterparts, being determined to be the leader of biomedical enterprises in Chinese innovation era!